Jafron Biomedical Co Ltd
300529
Company Profile
Business description
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Contact
No. 98, Science and Technology 6th Road
High-tech Zone
Guangdong Province
Zhuhai519085
CHNT: +86 7563619693
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
2,797
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,905.63 | 48.27 | 0.61% |
| DAX 40 | 24,274.93 | 57.56 | 0.24% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,112.50 | 23.82 | -0.26% |
| HKSE | 25,176.93 | 347.52 | -1.36% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,615.72 | 6.01 | 0.17% |